Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sight Sciences, Inc.SGHT · Entity 5537 | Director · President and CEO · 10% owner | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sight Sciences, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,092,819 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 29,653 · Balance 6,092,819 F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.87 to $9.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (i) 5,599,542 shares of Common Stock, and (ii) 493,277 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs").
F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.87 to $9.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes (i) 5,599,542 shares of Common Stock, and (ii) 493,277 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:40 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 29,653 | $9.05 | $268,330.00 |
DisclosureSEC source: 0001193125-26-414272 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,092,819 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.87 to $9.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 5,599,542 shares of Common Stock, and (ii) 493,277 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:31 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 28,684 | $5.42 | $155,467.28 |
DisclosureSEC source: 0001193125-26-296589 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,122,472 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $5.24 to $5.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 5,572,746 shares of Common Stock, and (ii) 549,726 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 29,244 | $3.70 | $108,202.80 |
DisclosureSEC source: 0001193125-26-142225 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,151,156 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $3.63 to $3.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 5,544,983 shares of Common Stock, and (ii) 606,173 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:48 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 154,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039555 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,180,400 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2026 and continuing through December 31, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $1,000,000 divided by the closing price of the Common Stock on the grant date, which was February 3, 2026. F2 · balance_after: Includes (i) 5,517,778 shares of Common Stock, and (ii) 662,622 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:54 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 22,362 | $6.62 | $148,036.44 |
DisclosureSEC source: 0001193125-26-018126 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,025,840 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 5,517,778 shares of common stock, and (ii) 508,062 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested. F4 · balance_after: The Reporting Person previously reported a grant of 87,800 RSUs on a Form 4 filed on February 11, 2022 (which was subsequently included under Table 1 on a Form 4 filed on January 5, 2023) and a grant of 176,600 RSUs on a Form 4 filed on March 21, 2023, which were awarded on February 9, 2022 and March 16, 2023, respectively. Of these RSU grants, 176,500 shares were inadvertently excluded from the Reporting Person's beneficially owned shares. The reported balance includes these previously excluded shares. Furthermore, the Reporting Person's Form 4 filed on February 16, 2024 inadvertently included under Column 5 of Table I 53,574 shares of common stock underlying the Reporting Person's stock options that were to vest within 60 days of the date of such filing. The reported balance on this Form 4 excludes the number of shares underlying such stock options. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 00:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 11,870 | $7.48 | $88,787.60 |
DisclosureSEC source: 0001193125-26-005006 · ownership.xml · nonDerivative · entry 2 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,925,276 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F3 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 25,356 | $7.43 | $188,395.08 |
DisclosureSEC source: 0001193125-26-005006 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,937,146 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.29 to $8.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:53 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 24,441 | $3.34 | $81,632.94 |
DisclosureSEC source: 0001193125-25-230558 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,962,502 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2025 Filed Jul 8, 2025 01:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 23,637 | $4.15 | $98,140.82 |
DisclosureSEC source: 0000950170-25-094426 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,986,943 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $4.06 to $4.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 01:56 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 24,174 | $2.30 | $55,672.72 |
DisclosureSEC source: 0000950170-25-050868 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,010,580 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| March 11, 2025 Filed Mar 14, 2025 01:54 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 358,423 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039080 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,034,754 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2025 and continuing through December 31, 2028, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $1,000,000 divided by the closing price of the Common Stock on the grant date, which was March 11, 2025. The RSUs have no expiration date. Read SEC document |
| January 16, 2025 Filed Jan 22, 2025 02:58 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 24,819 | $2.92 | $72,570.76 |
DisclosureSEC source: 0000950170-25-007514 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,676,331 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $2.845 to $3.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 11:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Tax withholdingCommon Stock | 12,047 | $3.58 | $43,128.26 |
DisclosureSEC source: 0000950170-25-003723 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,701,150 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, withheld by the Issuer to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 02:46 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 12,236 | $3.60 | $44,012.89 |
DisclosureSEC source: 0000950170-25-002530 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,713,197 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $3.55 to $3.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 01:57 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 12,727 | $5.99 | $76,183.82 |
DisclosureSEC source: 0000950170-24-112709 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,725,433 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 23:54 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 12,569 | $6.42 | $80,655.27 |
DisclosureSEC source: 0000950170-24-081729 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,738,160 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| April 03, 2024 Filed Apr 4, 2024 23:25 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 12,571 | $5.08 | $63,848.11 |
DisclosureSEC source: 0000950170-24-041986 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750,729 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:37 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 390,187 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016705 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,763,300 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2024 and continuing through December 31, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $1,670,000 divided by the closing price of the Common Stock on the grant date, which was February 14, 2024. The RSUs have no expiration date. F2 · balance_after: Includes 53,574 shares of Common Stock issuable upon the Reporting Person's exercise of options that shall vest within 60 days of the date hereof subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 21:49 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 15,917 | $5.16 | $82,195.39 |
DisclosureSEC source: 0000950170-24-005842 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,319,539 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:40 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Tax withholdingCommon Stock | 8,975 | $5.17 | $46,418.70 |
DisclosureSEC source: 0000950170-24-002609 · ownership.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,335,456 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes (i) 21,950 shares of Common Stock issued in connection with the vesting of RSUs on January 1, 2024, and (ii) 44,000 shares of Common Stock that will be issued in connection with the vesting of RSUs on January 15, 2024, subject to the Reporting Person's continued service through such date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 10:15 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantStock Option (Right to Buy) · Derivative | 225,700 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0000899243-23-009244 · doc4.xml · derivative · entry 2 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,700 Underlying: Common Stock · 225,700 shares Expires 2033-03-16 F3 · shares: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable in 48 equal monthly installments with the first installment vesting commencing on January 1, 2023 through January 1, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. F3 · derivative.exercise_date: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable in 48 equal monthly installments with the first installment vesting commencing on January 1, 2023 through January 1, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 10:15 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 176,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009244 · doc4.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,278,481 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments from January 15, 2024 through January 15, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). F2 · balance_after: Reflects shares of Common Stock beneficially owned by the Reporting Person as of the date hereof, excluding RSUs that do not vest within 60 days of this filing pursuant to Rule 13d-3(d)(1)(i). Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 11:30 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Tax withholdingCommon Stock | 8,251 | $12.21 | $100,744.71 |
DisclosureSEC source: 0000899243-23-000826 · doc4.xml · nonDerivative · entry 2 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,278,481 F3 · shares: Reflects shares of Common Stock withheld by the Issuer to cover the Reporting Person's tax liability in connection with the vesting of RSUs. F4 · price: Reflects the closing sale price of the Issuer's Common Stock as reported on The Nasdaq Global Select Market on December 30, 2022. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 11:30 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 87,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000826 · doc4.xml · nonDerivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,286,732 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person on February 9, 2022 under the Issuer's 2021 Incentive Award Plan (such grant, the "2022 RSU Grant"), as reported in Table II on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on February 11, 2022. Of the RSUs awarded to the Reporting Person under the 2022 RSU Grant, 25% vested on January 1, 2023, and an additional 25% vest on each of January 1, 2024, 2025, and 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The RSUs have no expiration date. F2 · balance_after: Includes 21,950 shares of Common Stock issued in connection with the January 1, 2023 vesting of the 2022 RSU Grant. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:05 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantStock Option (Right to Buy) · Derivative | 351,300 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0000899243-22-005828 · doc4.xml · derivative · entry 2 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,300 Underlying: Common Stock · 351,300 shares Expires 2032-02-09 F3 · derivative.exercise_date: The options vest and become exercisable in 48 substantially equal monthly installments with the first installment vesting on February 1, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:05 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantRestricted Stock Units · Derivative | 87,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-005828 · doc4.xml · derivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,800 Underlying: Common Stock · 87,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The Restricted Stock Units vest as to 25% on each of January 1, 2023; January 1, 2024; January 1, 2025 and January 1, 2026. The Restricted Stock Units have no expiration date. F2 · derivative.expiration_date: The Restricted Stock Units vest as to 25% on each of January 1, 2023; January 1, 2024; January 1, 2025 and January 1, 2026. The Restricted Stock Units have no expiration date. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 20:46 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantStock Option (Right to Buy) · Derivative | 58,753 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-21-028656 · doc4.xml · derivative · entry 1 Badawi Paul · CIK 0001870865 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,753 Underlying: Common Stock · 58,753 shares Expires 2031-07-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments with the first installment vesting on June 24, 2021, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.